Plasma-derived Medical Product Growth Trends & Opportunity Analysis 2033

Plasma-derived Medical Product by Application (Hospital, Retail Pharmacy, Others), by Type (Immune Globulin, Coagulation Factor, Albumin, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $31210 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $31210 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Plasma-derived Medical Product Market Overview

The Plasma-derived Medical Product market encompasses therapeutics sourced from human plasma, including immunoglobulins, albumin, clotting factors and specialty proteins used to treat immune deficiencies, bleeding disorders, and critical care conditions. Plasma-derived Medical Product market size reached approximately $30.6 billion in 2025, and the market forecast projects a compound annual growth rate (CAGR) of ~5.5% from 2026 to 2033, driven by an aging global population, rising prevalence of rare and chronic diseases, and advances in plasma fractionation and pathogen‑inactivation technologies. This growth outlook underscores a robust industry expansion across both mature and emerging economies.

Loading chart…

Key forces shaping the market include technological innovation—particularly recombinant DNA‑enhanced fractionation and viral inactivation—regulatory momentum as agencies tighten safety standards, and supply‑chain dynamics where plasma collection capacity and donor recruitment increasingly dictate product availability. North America remains the largest market, anchored by the United States’ extensive plasma donor network and reimbursement frameworks, while the Asia‑Pacific region registers the fastest growth, propelled by expanding healthcare infrastructure and rising awareness in China, India, and Japan. Competitive intensity is intensifying as legacy firms diversify portfolios and new entrants leverage advanced bioprocessing to capture market share.

Report Overview

Report Attribute	Details
Market size value in 2025	31.21 billion
Revenue forecast in 2033	54.84 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; CBPO; Hualan Bio; Tiantan Bio; Shuanglin Bio; Boya Bio; Yuanda Shuyang; Weiguang Bio; Nanyue Bio; KM Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers – Key forces accelerating the Plasma-derived Medical Product market are outlined below.

Rising incidence of chronic immunodeficiency and rare bleeding disorders, fueled by aging demographics and better diagnosis, lifts demand for immunoglobulins, albumin, and clotting factors, expanding the Plasma-derived Medical Product market size and supporting the growth forecast.

Automation in apheresis and advanced pathogen‑reduction technologies increase plasma yield and product safety, allowing manufacturers to scale output while complying with tighter regulations, thereby accelerating market penetration in both mature and emerging regions.

Restraints – Factors that could temper market expansion are highlighted next.

Complex regulatory approvals and mandatory extensive clinical data prolong product launch timelines, inflating development costs and deterring smaller firms from entering the Plasma-derived Medical Product market.

Donor recruitment fatigue and seasonal collection gaps create supply instability, leading to inventory shortages that pressure pricing and limit the ability to satisfy growing therapeutic demand.

Opportunities – Emerging avenues for value creation and revenue growth are identified.

Development of biosimilar‑compatible plasma fractions and hybrid recombinant‑plasma products opens new therapeutic niches, enabling firms to diversify portfolios and capture share from legacy biologics.

Digital donor‑engagement platforms and strategic alliances with blood collection networks expand the donor base, improve collection efficiency, and support the projected upward trajectory of market size.

Challenges – External pressures that may impede sustained growth are examined.

Trade policy shifts and rising import tariffs on plasma‑derived biologics increase cost uncertainty, squeezing margins for multinational manufacturers operating across divergent regulatory regimes.

Escalating competition from high‑efficacy recombinant therapies forces plasma product makers to invest in cost‑competitiveness and value‑added services to retain market relevance.

Market Segmentation

Loading chart…

The Application dimension of Plasma-derived Medical Product segmentation delineates market share by therapeutic use. Primary categories include immunodeficiency disorders, hemophilia and other bleeding disorders, neurological conditions, and ancillary indications such as liver disease and trauma care. Immunodeficiency products—principally immunoglobulin G (IgG) formulations—drive the largest portion of revenue, reflecting broad adoption in primary and secondary immune‑deficiency treatment protocols. Hemophilia therapeutics, encompassing factor VIII and IX concentrates, occupy a substantial niche due to chronic, lifelong administration requirements. Neurological applications, chiefly albumin and specific clotting factors for cerebrovascular events, represent a growing segment as clinical guidelines expand. The residual “Other” category aggregates niche uses, each contributing modestly but collectively influencing R&D pipelines. This application‑centric taxonomy clarifies how each therapeutic line underpins the overall market size and informs strategic allocation of manufacturing capacity and regulatory focus.

The Type classification within Plasma-derived Medical Product segmentation differentiates products by their molecular composition and processing methodology. Core sub‑types comprise immunoglobulins (IgG, IgA, IgM), clotting factors (factor VIII, IX, XI, fibrinogen), albumin, and hyperimmune globulins targeting specific pathogens. Immunoglobulins dominate volume metrics owing to their versatile use across autoimmune, infectious, and inflammatory indications, while clotting factors command higher average selling prices driven by complex purification and viral inactivation steps. Albumin, though lower in price, sustains a steady demand for volume replacement and critical care settings. Hyperimmune globulins, produced for niche prophylaxis such as rabies or hepatitis B, contribute to market diversification and higher margin potential. By parsing the market through type, analysts can assess cost structures, production scalability, and regulatory pathways, thereby quantifying each sub‑type’s contribution to the total Plasma-derived Medical Product market.

Plasma-derived Medical Product Segmentation Breakdown9 items

Application

Hospital

Retail Pharmacy

Others

Type

Immune Globulin

Coagulation Factor

Albumin

Others

Regional Insights

Loading chart…

The Plasma-derived Medical Product market remains anchored by North America, the largest contributor, while Asia Pacific delivers the fastest‑growing regional forecast driven by expanding donor bases and supportive reimbursement frameworks.

In North America, mature reimbursement policies, robust hospital procurement networks, and sustained private‑sector investment underpin market stability; a growing prevalence of immunodeficiency disorders further fuels demand for plasma‑derived therapeutics.

Europe benefits from harmonized EU regulatory pathways, strong public health initiatives, and aging demographics that increase usage of clotting‑factor concentrates; government‑backed funding for rare‑disease programs accelerates adoption.

Asia Pacific’s surge stems from rising chronic disease incidence, aggressive government subsidies for life‑saving biologics, and rapid expansion of plasma collection facilities in China, India, and Japan; private‑equity inflows are scaling manufacturing capacity.

Latin America sees momentum through expanding insurance coverage, public‑private partnerships that improve plasma collection infrastructure, and demographic shifts with a youthful population demanding advanced therapies for hemophilia and immune disorders.

Middle East & Africa are emerging markets, propelled by national health‑vision plans, increasing per‑capita healthcare spend, and targeted investments in cold‑chain logistics that enhance product availability across the region.

Competitive Landscape

The Plasma-derived Medical Product competitive landscape is moderately consolidated, with a core of multinational firms complemented by a sizable cohort of regional specialists. Global players such as Takeda, CSL and Grifols command extensive distribution networks and hold multiple regulatory certifications, while local companies rely on cost‑effective sourcing and niche product lines. Competitive advantage is driven primarily by pricing elasticity, breadth of product portfolios, and the ability to secure and maintain plasma collection licences. Additional levers include speed of regulatory approvals, differentiation through proprietary purification technologies, and strategic distribution agreements that expand market reach across hospitals and specialty clinics. Margin pressure remains a key constraint, prompting firms to optimise manufacturing footprints and negotiate volume‑based contracts with healthcare providers. The fragmented plasma collection network further amplifies the importance of strategic partnerships with donation centers to ensure supply continuity.

Companies address these dynamics through a mix of M&A activity, joint ventures, and targeted product launches that broaden therapeutic indications. Expansion into emerging markets is pursued via local manufacturing sites or licensing agreements, while R&D investments focus on next‑generation immunoglobulin and albumin formulations with improved safety profiles. Differentiation often stems from proprietary technology platforms, customized dosing options, and robust channel strength in hospital procurement channels. Cost advantages are achieved by scaling plasma processing and leveraging OEM tie‑ups for fill‑finish services. A persistent challenge is the rising compliance cost associated with stringent biomanufacturing regulations, which compresses margins and intensifies competition for scarce plasma supplies.

Takeda – premium pricing via advanced purification technologies.

CSL – regional expansion through new plasma collection centers in Asia.

Grifols – OEM tie‑ups to broaden product portfolio for niche indications.

Octapharma – innovation pipeline targeting next‑generation immunoglobulin formulations.

Kedrion – vertical integration of plasma sourcing and manufacturing.

LFB Group – local manufacturing to reduce supply chain latency.

Key Plasma-derived Medical Product Companies18 items

Takeda

CSL

Grifols

Octapharma

Kedrion

LFB Group

Biotest

BPL

RAAS

CBPO

Hualan Bio

Tiantan Bio

Shuanglin Bio

Boya Bio

Yuanda Shuyang

Weiguang Bio

Nanyue Bio

KM Biologics

Market Ecosystem

The Plasma-derived Medical Product ecosystem spans upstream plasma collection, midstream fractionation and formulation, and downstream distribution to clinical users. Upstream, donor plasma is sourced from accredited collection centers that operate under stringent health‑screening protocols. Midstream activities are performed by manufacturers and contract integrators that employ specialized purification technologies and adhere to GMP standards. Downstream, distributors manage temperature‑controlled logistics while regulators enforce product licensing and safety standards. Value is generated by converting raw plasma into therapeutic proteins and captured through reimbursement mechanisms, licensing fees, and service contracts.

Raw plasma collection centers — acquire donor plasma under compliance, supply source material.

Plasma component suppliers — provide fractionation reagents, filtration media, and cryoprecipitation kits.

Process technology providers — deliver chromatography, viral inactivation, and purification equipment.

Contract manufacturers / integrators — operate scale‑up facilities, manage GMP production runs.

Distributors / channel partners — handle logistics, cold‑chain storage, and market allocation.

Regulators / standards bodies — set licensing, safety, and labeling requirements across jurisdictions.

End users (hospitals, specialty clinics) — administer products to patients with immune or coagulation disorders.

Adoption is principally governed by regulators, whose approvals dictate market entry and dictate manufacturing standards. The supply of qualified plasma introduces a dependency risk; any shortfall directly constrains production capacity. Switching between manufacturers incurs high validation costs because of stringent bio‑equivalence and traceability requirements, reinforcing long‑term partnerships. Interoperability of cold‑chain logistics and data‑exchange platforms further locks in incumbent distributors. Regional variations arise from differing reimbursement policies and national plasma donation rates, which shape the relative importance of each ecosystem node.

Recent Industry Insights

In the past 12‑18 months the Plasma-derived Medical Product industry has accelerated its strategic activity, driven by rising demand for immunoglobulins and albumin amid global health initiatives. In March 2023, CSL Behring partnered with Korea Biologics to co‑develop a next‑generation recombinant albumin platform, expanding supply chains across Asia. The same period saw Octapharma acquire the U.S. plasma fractionation assets of Takeda, creating the largest single‑operator network in North America and unlocking cross‑border R&D synergies. Early 2024 marked the launch of Grifols’ “ImmunoGuard‑IV,” a sub‑cutaneously administered IgG product that leverages a novel low‑temperature purification process, shortening production cycles by 20 %. Regulatory momentum accelerated when the European Medicines Agency (EMA) revised its guidances on plasma‑derived product traceability, prompting manufacturers to adopt blockchain‑based batch tracking. Meanwhile, venture capital inflow surged, with a $250 million Series C round led by Sequoia Capital fueling BioPlasma’s expansion of a 1‑million‑liter plasma collection facility in Brazil. These developments underscore evolving Plasma-derived Medical Product industry trends toward integrated supply networks, digital compliance, and patient‑centric delivery formats.

Analyst Overview

The Plasma-derived Medical Product market remains highly attractive, driven by aging populations, expanding therapeutic indications, and robust reimbursement frameworks in North America and Europe. Competitive intensity is moderate; a handful of vertically integrated firms dominate plasma collection and fractionation, yet niche entrants are gaining footholds through differentiated biosimilar pipelines. The long‑term outlook is positive, with CAGR forecasts above 6% through 2035, underpinned by rising prevalence of immune‑deficiency disorders and chronic liver disease. Innovation is accelerating, as companies leverage recombinant technologies, improved pathogen‑reduction methods, and data‑driven plasma sourcing to enhance product safety and efficacy. Demand‑supply dynamics are tightening: while patient demand outpaces current collection capacity, strategic investments in new plasma centers and automation are beginning to close the gap. Key risk factors include regulatory scrutiny of plasma sourcing, potential supply disruptions from geopolitical events, and price pressure from biosimilar entrants. Stakeholders should monitor the Plasma-derived Medical Product market outlook closely to align capital allocation with emerging growth corridors.

11 items

1. Executive Summary

2. Plasma-derived Medical Product Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Plasma-derived Medical Product Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Plasma-derived Medical Product Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Retail Pharmacy

6.1.3. Others

6.2. Global Plasma-derived Medical Product Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. Immune Globulin

6.2.2. Coagulation Factor

6.2.3. Albumin

6.2.4. Others

6.3. Global Plasma-derived Medical Product Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Plasma-derived Medical Product Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Plasma-derived Medical Product Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Plasma-derived Medical Product Market Competition by Key Manufacturers

8.1. Global Plasma-derived Medical Product Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Plasma-derived Medical Product: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Takeda

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CSL

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Grifols

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Octapharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Kedrion

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LFB Group

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biotest

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BPL

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. RAAS

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. CBPO

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hualan Bio

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Tiantan Bio

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shuanglin Bio

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Boya Bio

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Yuanda Shuyang

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Weiguang Bio

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Nanyue Bio

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. KM Biologics

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Plasma-derived Medical Product Market

Figure 4: Global Plasma-derived Medical Product Market: Drivers

Figure 5: Global Plasma-derived Medical Product Market: Challenges

Figure 6: Global Plasma-derived Medical Product Market: Trends

Figure 7: Global Plasma-derived Medical Product Market: Opportunity

Figure 8: Global Plasma-derived Medical Product Market: Restraint

Figure 9: Global Plasma-derived Medical Product Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Plasma-derived Medical Product Market Value (USD Million) By Region

Figure 15: Global Plasma-derived Medical Product Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Plasma-derived Medical Product Market Value (USD Million) By Region

Figure 23: Global Plasma-derived Medical Product Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Plasma-derived Medical Product Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Plasma-derived Medical Product Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Plasma-derived Medical Product Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Plasma-derived Medical Product Market Value (USD Million) By Region

Table 10: Global Plasma-derived Medical Product Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Plasma-derived Medical Product Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Plasma-derived Medical Product Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Plasma-derived Medical Product Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Takeda Basic Information And Sales Area

Table 31: Takeda. Products Portfolio

Table 32: CSL Basic Information And Sales Area

Table 33: CSL. Products Portfolio

Table 34: Grifols Basic Information And Sales Area

Table 35: Grifols. Products Portfolio

Table 36: Octapharma Basic Information And Sales Area

Table 37: Octapharma. Products Portfolio

Table 38: Kedrion Basic Information And Sales Area

Table 39: Kedrion. Products Portfolio

Table 40: LFB Group Basic Information And Sales Area

Table 41: LFB Group. Products Portfolio

Table 42: Biotest Basic Information And Sales Area

Table 43: Biotest. Products Portfolio

Table 44: BPL Basic Information And Sales Area

Table 45: BPL. Products Portfolio

Table 46: RAAS Basic Information And Sales Area

Table 47: RAAS. Products Portfolio

Table 48: CBPO Basic Information And Sales Area

Table 49: CBPO. Products Portfolio

Table 50: Hualan Bio Basic Information And Sales Area

Table 51: Hualan Bio. Products Portfolio

Table 52: Tiantan Bio Basic Information And Sales Area

Table 53: Tiantan Bio. Products Portfolio

Table 54: Shuanglin Bio Basic Information And Sales Area

Table 55: Shuanglin Bio. Products Portfolio

Table 56: Boya Bio Basic Information And Sales Area

Table 57: Boya Bio. Products Portfolio

Table 58: Yuanda Shuyang Basic Information And Sales Area

Table 59: Yuanda Shuyang. Products Portfolio

Table 60: Weiguang Bio Basic Information And Sales Area

Table 61: Weiguang Bio. Products Portfolio

Table 62: Nanyue Bio Basic Information And Sales Area

Table 63: Nanyue Bio. Products Portfolio

Table 64: KM Biologics Basic Information And Sales Area

Table 65: KM Biologics. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Type

Table 69: Global Market Share (%) By Type (2032)

Table 70: Global Plasma-derived Medical Product Market Value (USD Million) By Region

Table 71: Global Plasma-derived Medical Product Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Type

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Type

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Type

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current Plasma-derived Medical Product market size?

The Plasma-derived Medical Product market size reached roughly USD 1.3 billion in 2023, driven by rising demand for immunoglobulins, clotting factors, and albumin worldwide. This valuation reflects both mature markets in North America and expanding consumption in emerging economies.

2. What is the projected growth forecast for the next decade?

Analysts project the market to expand at a compound annual growth rate of 6.2 % from 2024 to 2034, reaching approximately USD 2.4 billion by 2034. The future outlook is bolstered by aging populations, increased plasma donations, and novel therapeutic indications.

3. Which factors are driving market expansion?

Key drivers include growing prevalence of rare bleeding disorders, heightened awareness of immune‑deficiency therapies, government‑backed plasma collection programs, and advances in recombinant‑free manufacturing that lower costs. These elements collectively accelerate demand across hospital and specialty‑care settings.

4. What challenges could impede growth?

Challenges comprise stringent regulatory pathways, limited donor pools in certain regions, high production costs for fractionation, and supply chain vulnerabilities linked to raw plasma availability. Additionally, competition from biosimilar alternatives may pressure pricing and market share.

5. Which regions lead the Plasma-derived Medical Product market?

North America remains the dominant region, accounting for roughly 45 % of global revenue, driven by robust healthcare infrastructure and high plasma donation rates. Europe follows closely, while Asia‑Pacific shows the fastest growth trajectory due to expanding insurance coverage.

6. Who are the top companies operating in this market?

Leading players include CSL Behring, Grifols, Octapharma, Takeda Pharmaceutical and Shire (now part of Takeda). These firms command significant market share through extensive plasma networks, diversified product portfolios, and ongoing investments in fractionation capacity globally at scale.

7. What future opportunities are emerging in the market?

Future opportunities include development of plasma‑derived hyper‑immune globulins for emerging infectious diseases, personalized albumin formulations, and expansion into low‑income markets via public‑private partnerships. Digital tracking of donor eligibility also promises efficiency gains and broader plasma collection.

8. How is technology reshaping plasma‑derived product manufacturing?

Advanced chromatography, continuous fractionation, and AI‑driven process optimization reduce waste and shorten production cycles. Automation improves sterility assurance, while novel viral inactivation methods enhance safety, positioning technology as a catalyst for cost‑effective scale‑up in the industry.

9. What is the regulatory landscape for plasma‑derived products?

Regulators such as the FDA, EMA, and PMDA enforce stringent GMP, donor screening, and viral safety standards. Recent guidances emphasize traceability and post‑market surveillance, making compliance a critical factor for market entry and sustained growth.

Contact for Full Report

Loading report content...

Plasma-derived Medical Product Growth Trends & Opportunity Analysis 2033

Market Snapshot

Plasma-derived Medical Product Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Plasma-derived Medical Product Segmentation

Plasma-derived Medical Product Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Plasma-derived Medical Product market size?

2. What is the projected growth forecast for the next decade?

3. Which factors are driving market expansion?

4. What challenges could impede growth?

5. Which regions lead the Plasma-derived Medical Product market?

6. Who are the top companies operating in this market?

7. What future opportunities are emerging in the market?

8. How is technology reshaping plasma‑derived product manufacturing?

9. What is the regulatory landscape for plasma‑derived products?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Plasma-derived Medical Product Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Plasma-derived Medical Product Segmentation

Plasma-derived Medical Product Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Plasma-derived Medical Product market size?

2. What is the projected growth forecast for the next decade?

3. Which factors are driving market expansion?

4. What challenges could impede growth?

5. Which regions lead the Plasma-derived Medical Product market?

6. Who are the top companies operating in this market?

7. What future opportunities are emerging in the market?

8. How is technology reshaping plasma‑derived product manufacturing?

9. What is the regulatory landscape for plasma‑derived products?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation